beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis

T Miyata, O Oda, R Inagi, Y Iida, N Araki, N Yamada, S Horiuchi, N Taniguchi, K Maeda, T Kinoshita, T Miyata, O Oda, R Inagi, Y Iida, N Araki, N Yamada, S Horiuchi, N Taniguchi, K Maeda, T Kinoshita

Abstract

beta 2-Microglobulin (beta 2M) is a major constituent of amyloid fibrils in hemodialysis-associated amyloidosis, a complication of long-term hemodialysis patients. Amyloid fibril proteins were isolated from connective tissues forming carpal tunnels in hemodialysis patients with carpal tunnel syndrome. Two-dimensional polyacrylamide gel electrophoresis and Western blotting demonstrated that most of the beta 2M forming amyloid fibrils exhibited a more acidic pI value than normal beta 2M. This acidic beta 2M was also found in a small fraction of beta 2M in sera and urine from these patients, whereas heterogeneity was not observed in healthy individuals. We purified acidic and normal beta 2M from the urine of long-term hemodialysis patients and compared their physicochemical and immunochemical properties. Acidic beta 2M, but not normal beta 2M, was brown in color and fluoresced, both of which are characteristics of advanced glycation end products (AGEs) of the Maillard reaction. Immunochemical studies showed that acidic beta 2M reacted with anti-AGE antibody and also with an antibody against an Amadori product, an early product of the Maillard reaction, but normal beta 2M did not react with either antibody. Incubating normal beta 2M with glucose in vitro resulted in a shift to a more acidic pI, generation of fluorescence, and immunoreactivity to the anti-AGE antibody. The beta 2M forming amyloid fibrils also reacted with anti-AGE antibody. These data provided evidence that AGE-modified beta 2M is a dominant constituent of the amyloid deposits in hemodialysis-associated amyloidosis.

References

    1. N Engl J Med. 1988 May 19;318(20):1315-21
    1. J Clin Pathol. 1988 Feb;41(2):158-62
    1. Clin Nephrol. 1988 Sep;30(3):158-63
    1. Prog Clin Biol Res. 1989;304:1-22
    1. Kidney Int. 1989 Oct;36(4):675-81
    1. J Clin Invest. 1989 Dec;84(6):1813-20
    1. J Biol Chem. 1989 Dec 25;264(36):21597-602
    1. J Clin Invest. 1990 Feb;85(2):380-4
    1. Biochem Biophys Res Commun. 1990 May 16;168(3):1223-9
    1. Proc Natl Acad Sci U S A. 1990 Nov;87(22):9010-4
    1. J Biol Chem. 1991 Apr 25;266(12):7329-32
    1. J Exp Med. 1991 Sep 1;174(3):515-24
    1. N Engl J Med. 1991 Sep 19;325(12):836-42
    1. J Clin Invest. 1968 Apr;47(4):924-33
    1. J Exp Med. 1991 Oct 1;174(4):931-9
    1. J Clin Invest. 1992 Apr;89(4):1102-12
    1. Miner Electrolyte Metab. 1991;17(4):261-72
    1. J Biol Chem. 1992 May 25;267(15):10211-4
    1. Nature. 1970 Aug 15;227(5259):680-5
    1. J Biol Chem. 1968 Aug 10;243(15):4095-103
    1. Science. 1992 Oct 23;258(5082):651-3
    1. J Biol Chem. 1975 May 25;250(10):4007-21
    1. Science. 1981 Jan 30;211(4481):491-3
    1. Immunol Lett. 1983;7(2):61-4
    1. Proc Natl Acad Sci U S A. 1984 May;81(9):2684-8
    1. Biochem Biophys Res Commun. 1985 Jun 28;129(3):701-6
    1. Proc Natl Acad Sci U S A. 1985 Sep;82(17):5588-92
    1. Biochem Biophys Res Commun. 1985 Sep 30;131(3):1063-8
    1. J Exp Med. 1985 Dec 1;162(6):2163-8
    1. Lab Invest. 1985 Dec;53(6):705-9
    1. Nature. 1986 Aug 7-13;322(6079):547-9
    1. Proc Natl Acad Sci U S A. 1986 Oct;83(20):7908-12
    1. Kidney Int. 1986 Sep;30(3):385-90
    1. J Immunol. 1987 Nov 1;139(9):3132-8
    1. J Clin Pathol. 1987 Oct;40(10):1247-51
    1. Carbohydr Res. 1987 Sep 15;167:211-20
    1. Science. 1988 Jun 10;240(4858):1546-8

Source: PubMed

3
Se inscrever